Latest News | Revenue of Domestic API Firms to See 7-8 Pc Increase by 2029: Report

Get latest articles and stories on Latest News at LatestLY. Revenue of domestic active pharmaceutical ingredients producing firms is expected to see a 7-8 per cent rise by 2029, rating agency Icra said on Monday.

New Delhi, Aug 12 (PTI) Revenue of domestic active pharmaceutical ingredients producing firms is expected to see a 7-8 per cent rise by 2029, rating agency Icra said on Monday.

The rating agency expects the revenues of its sample set of companies to expand at a CAGR of 7-8 per cent between 2023 and 2029, from an estimated size of USD 13-14 billion in 2023.

Also Read | Shillong Teer Results Today, August 12 2024: Check Winning Numbers, Result Chart for Shillong Morning Teer, Shillong Night Teer, Khanapara Teer, Juwai Teer and Jowai Ladrymbai.

"This will be driven by a steady ramp-up in the pharmaceutical formulations industry, which in turn, will be aided by an increasing geriatric population, higher prevalence of chronic diseases, and rising demand for contract manufacturing with global customers looking to diversify their supply chain along with greater focus on domestic sourcing," Icra said in a statement.

It also forecasts the operating profit margin (OPM) of its sample set of companies to improve mildly in FY2025, it added.

Also Read | Punjab State Dear Rakhi Bumper 2024 Draw Date and Time: Punjab State To Declare Dear Rakhi Bumper Lottery Results on This Day at punjabstatelotteries.gov.in, Know Ticket Prices and Winning Amount.

Domestic API industry players faced considerable volatility in earnings over FY2021-FY2023 on account of multiple headwinds such as rising raw material costs.

The production cost went up due to elevated crude oil prices and pandemic-induced lockdowns in China, resulting in a shortage of key starting materials (KSMs) and APIs globally among others, Icra said.

"Given the subsequent remission in many of these headwinds, ICRA expects revenues of its sample set of companies to grow by 7-8 per cent in FY2025, post an estimated increase of 3-5 per cent in FY2024," Icra Vice President & Sector Head – Corporate Ratings Deepak Jotwani said.

However, the impact of subdued demand from some key export markets such as Europe and tensions in the Red Sea impacting supply chain and freight costs will continue to be monitored, he added.

India imported APIs and bulk drugs worth Rs 37,700 crore in FY2024, accounting for 35 per cent of its total API requirement. Imports from China accounted for 70 per cent, Icra stated.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)

Share Now

Share Now